Evoke Pharma, Inc. (EVOK)
| Previous close | 1.2600 |
| Open | 1.2300 |
| Bid | 1.1100 x 900 |
| Ask | 1.5200 x 1000 |
| Day's range | 1.2000 - 1.2350 |
| 52-week range | 0.9190 - 5.9600 |
| Volume | |
| Avg. volume | 14,277 |
| Market cap | 4.112M |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
GIMOTI now holds four listed patents with coverage through 2029SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its recently issued U.S. patent related to GIMOTI, No. 11,813,231 is now listed in the U.S. Food and Drug Administration (FDA) publication, “Approved Drug Products with Th
- GlobeNewswire
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
The Company Will Submit for FDA Orange-Book Listing in the Near TermSOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,813,231 titled “Nasal Formulations of Metoclopramide”, pertaining to the Company’s com
- GlobeNewswire
Evoke Pharma Reports Third Quarter 2023 Financial Results
38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting SOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDA
